Hodgkin Lymphoma Trial Results
- Reducing Treatment Intensity Doesn't Compromise Results in Early-Stage Hodgkin Lymphoma
(Posted: 09/27/2010) - Reducing the dose of chemotherapy and radiotherapy did not compromise treatment efficacy in patients with early-stage, low-risk Hodgkin lymphoma but led to fewer side effects, according to a study published August 12, 2010, in the New England Journal of Medicine.
- Drug Slows Progression of Cutaneous T-Cell Lymphoma
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.